Healthcare's Valuation Disconnect Signals Opportunity for Asia's Wealth Allocators
The healthcare sector is currently trading at a discount to the broader market, presenting a compelling opportunity for wealth allocators in Asia. This article explores the reasons behind this disconnect and the potential benefits for investors.
A Sector in Distress, Yet with Robust Fundamentals
Healthcare has been a challenging sector for investors over the past two years, with political uncertainty in the United States and rising interest rates contributing to its underperformance. However, beneath the surface, the healthcare sector's fundamentals remain strong. The resolution of the most-favored-nation pricing dispute with the US government has removed a significant political overhang, stabilizing the sector.
Pharma and large-cap biotech companies have shown resilience, with small and mid-cap biotech names outperforming due to strong clinical results and acquisition activity. Healthcare providers, particularly US health insurance companies, have also shown signs of improvement, with first-quarter 2026 results indicating that premiums are high enough to cover medical costs.
The Valuation Opportunity
The valuation disconnect is evident when comparing the healthcare sector to the broader market. The MSCI World Healthcare Index trades at approximately 17 times forward earnings, compared to 21 times for the S&P 500. This discount is well below the long-term average, presenting a compelling entry point for investors.
Medtech, a sub-sector of healthcare, is experiencing a more pronounced valuation dislocation. Historically trading at 24-25 times earnings, it has compressed to around 18 times, despite strong organic revenue and earnings growth. This presents a promising opportunity for investors, but it will require catalysts to drive multiples higher.
Innovation as the Growth Engine
Innovation is a key driver of long-term growth in the healthcare sector. Several areas, such as cardiovascular medicine and medtech, are creating new revenue pools through the development of novel products and treatment modalities.
In cardiovascular medicine, lipoprotein(a) (Lp(a)) represents a large untapped opportunity. Elevated levels of Lp(a) affect one in five people and cannot be managed through diet or exercise. Several companies, including Novartis and Amgen, are developing therapies for this condition, with late-stage trials expected to deliver data in 2026.
Medtech is also seeing significant advancements, with robotic surgery systems like Intuitive Surgical's Da Vinci 5 incorporating AI-driven features for improved surgical training and performance analytics.
AI as an Enabler, Not a Disruptor
Artificial intelligence (AI) is playing a crucial role in healthcare, but it is primarily an efficiency tool rather than a disruptor. In pharma and biotech, AI is accelerating drug development, improving patient selection for clinical trials, and predicting toxicity profiles, potentially saving billions in costs.
For health insurance companies, AI enables automation of invoice processing and contract management. In medtech, heavy regulatory requirements create natural barriers to software disruption, giving hardware-based businesses a head start in adopting AI.
M&A as a Structural Imperative
Patent expirations pose a significant risk to big pharma, with hundreds of billions in revenue at stake. Mergers and acquisitions (M&A) are an imperative for these companies to maintain their market position. The 20 largest biopharma companies hold over $1 trillion in combined cash and debt capacity, enabling them to pursue major transactions.
Building the Case for Allocation
Healthcare remains structurally underweight in most portfolios, despite its defensive qualities and innovation-driven growth. Wealth managers and family office professionals are increasingly recognizing the sector's potential as a complement to concentrated technology positions.
Bellevue Asset Management, a specialist healthcare investor, manages over $6 billion in publicly listed healthcare equities and employs a team of investment professionals with diverse backgrounds. The firm believes that the current dislocation represents a window of opportunity for disciplined allocators to gain exposure to a sector with strong fundamentals and growth potential.
In conclusion, the healthcare sector's valuation disconnect presents a unique opportunity for wealth allocators in Asia. With robust fundamentals, innovation driving growth, and a favorable investment environment, healthcare is a sector that investors should consider for their portfolios.
